ArticleChemistry & biodiversity2026
Aryltetralin Lignan Glycosides From the Leaves of Viburnum cylindricum and Their Enzyme Inhibitory Activity.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Viburnum cylindricum Buch. -Ham. ex D. Don is a commonly used medicinal Viburnum species containing abundant bioactive secondary metabolites. In this study, 14 aryltetralin lignan glycosides, including three previously undescribed ones, viburindrosides A-C (1-3), along with two rare variable 9-O-2'-aryltetralin lignan glycosides (13 and 14), were isolated from V. cylindricum leaves by utilizing a liquid chromatography-tandem mass spectrometry-guided strategy. The structures of these compounds were elucidated by spectroscopic data, experimental and calculated electronic circular dichroism spectra, and chemical methods. In addition, the activity assessment results indicated that among all isolates, compounds 13 and 14 exhibited the strongest α-glucosidase inhibitory activity with the half-maximal inhibitory concentration (IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.